Literature DB >> 2878345

Adverse effects associated with the newer inotropic agents.

M W Webster, D N Sharpe.   

Abstract

The ideal inotropic agent should be available for both parenteral and oral administration and be potent and effective long term without significant adverse effects. In recent years, numerous new agents have been developed in an attempt to find a more potent, less toxic alternative to digoxin. beta-Agonists, while useful when given parenterally short term, appear to have their long term oral application limited by adverse effects and the development of tolerance. A number of other non-catecholamine agents, most of which have both inotropic and vasodilator actions, have also been studied. Adverse effects have been relatively frequent and occasionally severe. Of these newer agents none has yet been proven in clinical trials to be safe and effective in the long term.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2878345     DOI: 10.1007/bf03259847

Source DB:  PubMed          Journal:  Med Toxicol        ISSN: 0112-5966


  49 in total

1.  MDL 17,043: short- and long-term cardiopulmonary and clinical effects in patients with heart failure.

Authors:  S A Rubin; L Tabak
Journal:  J Am Coll Cardiol       Date:  1985-06       Impact factor: 24.094

2.  Activating effects of AR-L 115 BS on the Ca2+ sensitive force, stiffness and unloaded shortening velocity (Vmax) in isolated contractile structures from mammalian heart muscle.

Authors:  J W Herzig; K Feile; J C Rüegg
Journal:  Arzneimittelforschung       Date:  1981

3.  Intravenous and oral prenalterol in congestive heart failure. Effects on systemic and coronary hemodynamics and myocardial catecholamine balance.

Authors:  D W Wahr; K Swedberg; M Rabbino; M J Hoyle; D Curran; W W Parmley; K Chatterjee
Journal:  Am J Med       Date:  1984-06       Impact factor: 4.965

4.  Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study.

Authors:  D N Sharpe; J Murphy; R Coxon; S F Hannan
Journal:  Circulation       Date:  1984-08       Impact factor: 29.690

5.  Amrinone in the treatment of chronic cardiac failure.

Authors:  M J Likoff; K T Weber; V Andrews; J S Janicki; M S Sutton; H Wilson; M L Rocci
Journal:  J Am Coll Cardiol       Date:  1984-05       Impact factor: 24.094

6.  The effects of amrinone on platelet count, survival and function in patients with congestive cardiac failure.

Authors:  P T Wilmshurst; S F Al-Hasani; M J Semple; A S Hamblin; P G Kioy; G F Lucas; G F Savidge; M M Webb-Peploe
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

7.  Amrinone-induced thrombocytopenia.

Authors:  J Ansell; C Tiarks; J McCue; N Parrilla; J R Benotti
Journal:  Arch Intern Med       Date:  1984-05

8.  Hemodynamic effects of oral pirbuterol in chronic severe congestive heart failure.

Authors:  N A Awan; M K Evenson; K E Needham; T O Evans; J Hermanovich; C R Taylor; E Amsterdam; D T Mason
Journal:  Circulation       Date:  1981-01       Impact factor: 29.690

9.  Is digoxin really important in treatment of compensated heart failure? A placebo-controlled crossover study in patients with sinus rhythm.

Authors:  J L Fleg; S H Gottlieb; E G Lakatta
Journal:  Am J Med       Date:  1982-08       Impact factor: 4.965

10.  Heart failure in outpatients: a randomized trial of digoxin versus placebo.

Authors:  D C Lee; R A Johnson; J B Bingham; M Leahy; R E Dinsmore; A H Goroll; J B Newell; H W Strauss; E Haber
Journal:  N Engl J Med       Date:  1982-03-25       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.